BioPharmSignal logoBioPharmSignal

Biotech News

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

AnaptysBio, Inc. (ANAB)AnaptysBio, Inc.Financing

Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First

Related news

HOWLWerewolf Therapeutics2026-08-21 12:00 EST

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

HCWBHCW Biologics2026-07-29 13:06 EST

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

STTKShattuck Labs2026-06-10 04:21 EST

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

CRVSCorvus Pharmaceuticals2026-06-09 11:30 EST

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

STTKShattuck Labs2026-06-09 12:00 EST

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

BCTXBriaCell2026-06-02 20:05 EST

BriaCell Therapeutics Announces Closing of Offering

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

BCTXBriaCell2026-05-31 23:59 EST

BriaCell Therapeutics Announces Pricing of Offering

View all latest news

AnaptysBio, Inc.

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck...

Recent company news

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-05-11 13:15 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-05-04 20:15 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

ANABAnaptysBio, Inc.2026-04-24 19:40 EST

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

ANABAnaptysBio, Inc.2026-04-20 13:15 EST

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Stock data

Close
57.74 USD
Market cap
1.49B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States